Medicine
fromTNW | Health-Tech
12 hours agoKupando raises 10M more to take its immunity drug into the clinic
Kupando raised €10 million in Series A extension funding to advance KUP101, a dual TLR agonist, toward first human trials for solid tumors and drug-resistant infections.